Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐19

摘要

Antithrombotic guidance statements for hospitalized patients with coronavirus disease 2019 (COVID‐19) suggest a universal thromboprophylactic strategy with potential to escalate doses in high‐risk patients. To date, no clear approach exists to discriminate patients at high risk for venous thromboembolism (VTE).